Investing.com -- Eisai Co (OTC: ESAIY ). stock rose 0.4% on the day after initially trading in the red, as investors digested the company’s quarterly results that showed strong growth in sales of its ...

Eisai and Biogen's Alzheimer's drug Leqembi continued to slow progress of the disease with no new safety issues four years ...

Long-term data presented at the Alzheimer’s Association International Conference show Leqembi can help patients stay in the ...

Eisai: Leqembi Approved In EU (Rating Downgrade) Jun. 10, 2025 2:46 AM ET Eisai Co., Ltd. (ESALF) Stock, ESAIY Stock ESALF, ESAIY Valkyrie Trading Society Investing Group Leader ...

--BioArctic AB's partner Eisai today announced that Leqembi sales are expected to total JPY 76.5 billion for their fiscal year 2025, corresponding to a 73 percent growth compared to the previous ...

LEQEMBI’s FDA approval was based on Phase 3 data from Eisai’s, global Clarity AD clinical trial, in which it met its primary endpoint and all key secondary endpoints with statistically significant ...

Eisai serves as the lead of LEQEMBI development and regulatory submissions globally with both Eisai and Biogen co-commercializing and co-promoting the product and Eisai having final decision-making ...

Eisai aims to submit a LEQEMBI SC formulation Biologics License Application (BLA) with the U.S. Food and Drug Administration by March 31, 2024. 2.

FDA Accepts Eisai’s Filing of LEQEMBI® (lecanemab-irmb) Supplemental Biologics License Application for IV Maintenance Dosing for the Treatment of Early Alzheimer’s Disease ...

BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai today announced that Leqembi sales are expected to total JPY 76.5 billion (approximately SEK 5.1 billion) for their fiscal year (FY ...

BioArctic AB's (publ) (NASDAQ STOCKHOLM: BIOA B) partner Eisai today said that they expect Leqembi sales to total JPY 56.5 billion (approximately SEK 4 billion) for their fiscal year (FY) 2024 ...